Seattle institute lands $18m funding to develop RNA vaccine for chikungunya
Pharmaceutical Technology
AUGUST 3, 2023
AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.
Pfizer begins plan to challenge Shingrix with an mRNA vaccine
Bio Pharma Dive
FEBRUARY 10, 2023
The pharma and partner BioNTech have kicked off the first human trial of a messenger RNA shot for shingles, believing there’s room to clear the high bar set by GSK’s rival vaccine.
Vaccine 
358
358 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Moderna and Pfizer, having shown speed with coronavirus vaccines, see opportunity in seasonal flu
Bio Pharma Dive
SEPTEMBER 17, 2020
Both companies believe the messenger RNA technology they're using in their coronavirus vaccines could be applied to create a better flu shot.
Vaccine 329
329 
Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology
Bio Pharma Dive
AUGUST 26, 2022
The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.
Vaccine 261
261 
BioNTech targets infectious diseases for vaccine development
Pharmaceutical Technology
MARCH 28, 2023
Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%
Vaccine 276
276 
How did pharma develop a vaccine so quickly?
World of DTC Marketing
DECEMBER 29, 2020
OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.
Vaccine 307
307 
Moderna signs contract to supply Covid-19 booster vaccines to the US
Pharmaceutical Technology
AUGUST 1, 2022
Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.
Vaccine 289
289 
BioNTech Founders Predict Cancer Vaccine Is Only Years Away
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 16, 2022
The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.
Vaccine 242
242 
GreenLight and US NIH partner to develop Covid-19 vaccine for variants
Pharmaceutical Technology
AUGUST 1, 2022
GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.
Vaccine 245
245 
Merck and Moderna partner to develop and sell cancer vaccine
Pharmaceutical Technology
OCTOBER 14, 2022
German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.
Vaccine 289
289 
Merck and Orna partner for RNA technology-based vaccines and therapies
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.
RNA 147
147 
US FDA grants Fast Track status for Pfizer-BioNTech’s combination vaccine
Pharmaceutical Technology
DECEMBER 11, 2022
The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.
Vaccine 289
289 
Pfizer’s New RSV Vaccine TV Commercial Calls for Protecting Moments
XTalks
NOVEMBER 15, 2024
Pfizer released a new respiratory syncytial virus (RSV) vaccine TV commercial, titled “Your Moments Are Worth Protecting: Celebration” as part of its ongoing campaign to raise awareness about the importance of vaccination against RSV. Moderna entered the RSV vaccine arena this year with the very first mRNA-based RSV vaccine.
Vaccine 105
105 
Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run
Pharmaceutical Technology
AUGUST 2, 2022
Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.
Engineer 262
262 
FDA revokes EUAs of Pfizer/BioNTech’s and Moderna’s original Covid-19 vaccines
Pharmaceutical Technology
MAY 2, 2023
4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5
Vaccine 52
52 
Health Canada grants approval for Moderna’s Covid-19 vaccine in children
Pharmaceutical Technology
JULY 15, 2022
Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada.
Vaccine 264
264 
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
Pharmaceutical Technology
MAY 15, 2024
CircRNA is still in early days of development, but could be in trials as vaccines, therapeutics and biomarkers in the next few years.
RNA 147
147 
Sanofi signs mRNA vaccine development deal with IDT Australia
Pharmaceutical Technology
APRIL 16, 2024
Sanofi has signed an agreement with IDT Australia for preclinical formulation development of its messenger RNA (mRNA) vaccines.
Vaccine 147
147 
RNA glioblastoma vaccine shows promise in first human trial
pharmaphorum
MAY 2, 2024
A personalised vaccine for the aggressive brain cancer glioblastoma developed has shown encouraging signs of efficacy in its first human trial.
RNA 115
115 
BioNTech inaugurates mRNA vaccine manufacturing facility in Rwanda
Pharmaceutical Technology
DECEMBER 19, 2023
BioNTech has inaugurated a new messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda, which will have BioNTainers.
Manufacturing 130
130 
HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India
Pharmaceutical Technology
JUNE 30, 2022
HDT Bio has received Emergency Use Approval from Indian regulators for its Covid-19 vaccine, Gemcovac. The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. HDT Bio CEO Steve Reed said: “Our saRNA vaccine is a game-changer.
Vaccine 162
162 
mRNA Tech Used in COVID-19 Vaccines Could be Used to Cure HIV, Cancer and More
BioSpace
APRIL 11, 2021
Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.
Vaccine 142
142 
FDA authorizes Novavax’s COVID-19 vaccine for teens
Bio Pharma Dive
AUGUST 22, 2022
The decision will make a third vaccine available for children 12 to 17 years old in the U.S., giving them an option that doesn’t use the messenger RNA technology of shots by Pfizer and Moderna.
Vaccine 130
130 
Regulators questioned integrity of Pfizer/BioNTech vaccine, leaked files show
pharmaphorum
MARCH 16, 2021
European regulators questioned the integrity of early batches of Pfizer/BioNTech’s mRNA vaccine, although the matter was resolved before approval, according to information leaked online following a cyberattack. As it conducted its analysis of the vaccine in December, the European Medicines Agency’s systems were targeted by unknown hackers.
Regulation 138
138 
mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next?
STAT News
NOVEMBER 21, 2022
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19 vaccines are just the beginning.” Read the rest…
Vaccine 105
105 
UTMB and HDT Bio receive US funding for vaccine development
Pharmaceutical Technology
NOVEMBER 30, 2022
in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.
Vaccine 147
147 
COVID-19 Messenger RNA Vaccination and Myocarditis
JAMA Internal Medicine
OCTOBER 3, 2021
Several recent case series have described acute myocarditis after COVID-19 messenger RNA (mRNA) vaccination. While the cardiac complications of vaccines are important, discussion has been limited by small sample sizes that lack gender and racial and ethnic diversity. 414 fully vaccinated individuals). women and 31.2%
RNA 67
67 
GreenLight Biosciences and Samsung Biologics to build mRNA vaccine manufacturing capacity
BioPharma Reporter
NOVEMBER 25, 2021
GreenLight Biosciences and CDMO Samsung Biologics have announced a partnership agreement, with Samsung Biologics to manufacture GreenLightâs messenger RNA COVID-19 vaccine candidate at commercial scale.
Manufacturing 105
105 
Safety Evaluation of the Second Dose of mRNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
JAMA Internal Medicine
JULY 25, 2021
This case series study examines the safety of second doses of messenger RNA COVID-19 vaccines after first-dose allergic reactions.
Vaccine 111
111 
An mRNA vaccine strategy under study to fight the flu—as a shot and intranasal spray
Medical Xpress
DECEMBER 30, 2022
Messenger RNA vaccine technology, once an arcane area of research, became household terminology because of the COVID-19 pandemic, and now scientists are working on an mRNA flu vaccine strategy that, at least in this study, involves a first dose administered as a shot but a booster administered as an mRNA nasal spray.
Vaccine 111
111 
Leading innovators in flavivirus vaccine components
Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.
Vaccine 130
130 
Moderna seeks FDA EUA for Covid-19 booster vaccine
Pharmaceutical Technology
AUGUST 24, 2022
Mode rna has submitted an application to the US Food and Drug Administration (FDA) to obtain emergency use authorization (EUA) for mRNA-1273.222, its BA.4/BA.5 5 Omicron-targeting bivalent booster vaccine for Covid-19. The submission is made for a 50µg booster dose of the vaccine for usage in adults aged 18 years and above.
Vaccine 130
130 
Covid-19 vaccines were a success, but mRNA still has a delivery problem. Two startups have an unorthodox solution
STAT News
NOVEMBER 16, 2022
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19 vaccines are just the beginning.”
Vaccine 98
98 
Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score
STAT News
JANUARY 19, 2023
And do normal people care about messenger RNA? We also discuss the latest news in the life sciences, including new vaccines for a vexing infection and the future of mRNA. Where do new drugs come from? Does science need billionaires? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.
Vaccine 115
115 
H2 2022 to see the decline of Covid-19 vaccines as forecasts decrease
Pharmaceutical Technology
JANUARY 30, 2023
According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. Of these 22 vaccines, mRNA-derived vaccines dominate, with Comirnaty and Moderna’s Spikvax accounting for 88% of 2022 sales, with 58% and 30%, respectively.
Vaccine 130
130 
UK prepares for decision on AZ/Oxford vaccine as COVID cases soar
pharmaphorum
DECEMBER 24, 2020
The UK’s COVID-19 vaccination programme could get a speed boost, with the country’s drugs regulator expected to make a decision on a shot from Oxford University/AstraZeneca in the next few days. Just how this will be viewed by regulators is unclear, as are the plans to distribute the vaccine.
Vaccine 126
126 
Novavax’s Covid-19 vaccine wins backing of CDC advisory panel
STAT News
JULY 19, 2022
An expert panel that advises the Centers for Disease Control and Prevention on vaccine policy voted Tuesday to recommend use of Novavax’s Covid-19 vaccine — an achievement a long time in the making for the Gaithersburg, Md.-based based company.
Vaccine 98
98 
Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication
Pharmaceutical Technology
JUNE 8, 2023
Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.
Vaccine 130
130 
Noxopharm in-licenses novel RNA tech for drug discovery and vaccines
BioPharma Reporter
DECEMBER 6, 2021
Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.
RNA 52
52 
BioNTech, CureVac claim bulk of Germany’s €750m COVID-19 vaccines fund
pharmaphorum
SEPTEMBER 16, 2020
In May, Germany pledged to provide up to €750 million ($889 million) in funding to support vaccines against COVID-19, and the main recipients have now been revealed – BioNTech, CureVac and IDT Biologika – which are all German biotechs. Both of these vaccines are based on RNA and in phase 3 and phase 1 testing, respectively.
Vaccine 86
86 
UK faces “V-Day” and largest ever vaccination programme
pharmaphorum
DECEMBER 7, 2020
Tuesday has been dubbed “V-day” in the UK, when the first doses of Pfizer/BioNTech’s coronavirus vaccine will be distributed to the public outside of a clinical trial. Health secretary Matt Hancock reportedly came up with the wartime analogy to describe what will be the largest scale vaccination programme in the country’s history.
Vaccine 100
100 
Covid-19 vaccine success bolsters nanoparticle drug delivery research
Pharmaceutical Technology
APRIL 24, 2023
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages.
Drug Delivery 147
147 
Merck gets on board with Moderna cancer vaccine in $250m deal
pharmaphorum
OCTOBER 12, 2022
Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. As we all know, cancer vaccines have had a rough history. The post Merck gets on board with Moderna cancer vaccine in $250m deal appeared first on.
Vaccine 105
105 
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief
pharmaphorum
NOVEMBER 30, 2021
GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from Pfizer. His most recent role at Pfizer was chief scientific officer for RNA and viral vaccines, a position he held for more than six years. Phil Dormitzer.
Vaccine 98
98 
Let's personalize your content